2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
Avatar

2020 ASCO Update on CML: How Does Ponatinib Dose Reduction Affect Response in CP Disease?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Michael Deininger
By 2020 ASCO Virtual Direct™ Highlights FEATURING Michael Deininger
0 views
October 12, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri
Hematologic Oncology
08:07
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on R/R AML: Is AMG 330 Safe and Tolerable?

Feat. M. Deininger
10:21
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Newly Diagnosed AML: How Safe Is ENA+AZA Combina…

Feat. M. Deininger
06:41
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on IDH1-Mutated AML: How Tolerated is IVO/VEN/AZA C…

Feat. M. Deininger
09:47
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on CML: How Does Ponatinib Dose Reduction Affect Re…

Feat. M. Deininger